GINKGO BIOWORKS HOLDINGS INC DNA
ASignal's systematic analysis rates DNA as Bearish.
Reflects the latest available analysis · analyzed Nov 4, 2026
The case on DNA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin (68.04%) indicating pricing power
- Healthy balance sheet with current ratio of 4.57x and quick ratio of 4.33x
- Debt-to-equity ratio of 0.96x is moderate for biotech sector
- Positive free cash flow trend relative to cash burn (improving efficiency)
- Negative profit margin (-219.61%) and operating margin (-284.99%)
- Negative return on equity (-59.94%) and return on assets (-16.72%)
- Declining revenue growth (YoY change: -48.50%)
- Negative operating cash flow ($-170.24M)
- EV/EBITDA of -3.16x suggests valuation challenges
- Forward P/E of -3.71x indicates unprofitable earnings outlook
See the full verdict on DNA
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes DNA
Most investors never get a second opinion, let alone several. ASignal runs DNA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.